Search clinical trials for: SAR342434

Total 5 results

Sanofi

Completed

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes

Type 1 Diabetes

Germany
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (SORELLA1)

Type 1 Diabetes Mellitus

Japan, Spain, Germany, United States, France, Hungary, Poland, Russian Federation
Sanofi

Completed

A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes

Type 1 Diabetes

Germany
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine (SORELLA2)

Type 2 Diabetes Mellitus

United States, Argentina, Chile, Colombia, Germany, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Turkey

3

Subscribe